No Data
No Data
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
Merck (MRK.US) terminates Phase III study of PD-1+TIGIT combination therapy as first-line treatment for extensive-stage small cell lung cancer.
On August 8, Merck (MRK.US) announced that, following the recommendation of an independent data monitoring committee (DMC), the development of KeyVibe-008 in Phase III will be terminated.
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion
Merck Has Agreed To Acquire CN201, An Investigational Clinical-stage Bispecific Antibody For B-cell Associated Diseases, From A Privately Held Curon Biopharmaceutical For An Upfront Payment Of $700M In Cash And Up To $600M In Milestone Payments
Express News | Merck & Co Inc - to Update Financial Outlook in Q3 2024